Dihexa vs Cerebrolysin
These compounds occupy opposite ends of the neurotrophic spectrum. Dihexa is a single, well-characterised small molecule with an exceptionally strong preclinical synaptogenesis signal and no human data. Cerebrolysin is a complex biological preparation with decades of clinical use in approving jurisdictions and a correspondingly broad — but more mechanistically diffuse — evidence base.
Side-by-side
| Dihexa | Cerebrolysin | |
|---|---|---|
| Type | Single small peptide (hexapeptide) | Standardised multi-component preparation |
| Source | Synthetic (angiotensin IV-derived) | Enzymatic digest of porcine brain |
| Primary mechanism | HGF/c-Met agonism, synaptogenesis | Mimics multiple neurotrophic factors (BDNF, NGF, GDNF) |
| Route | Oral (in research) | Intravenous / intramuscular |
| Evidence | Strong preclinical; no human trials | Substantial clinical-trial body in stroke, dementia |
| Approved use | None | Approved in several jurisdictions (not UK/US/EMA-centralised) |
| UK status | Research chemical | Not licensed in the UK |
The fundamental difference
Dihexa: depth, not breadth
One molecule, one principal target (HGF/c-Met), one principal effect (synaptogenesis). The preclinical literature is among the strongest in the cognitive-peptide field, but the absence of human trials is a meaningful gap — and the c-Met pathway carries non-trivial theoretical safety questions that have not been answered.
Cerebrolysin: breadth, not depth
Many active components, multiple pathways, pleiotropic effects. The clinical evidence base is substantial; the mechanistic clarity is correspondingly weaker because the effects are not attributable to a single molecular handle. Parenteral administration is required.